Exact Sciences Stockholders Overwhelmingly Approve Acquisition by Abbott

Key Facts

1Exact Sciences (EXAS) stockholders voted to approve the proposed acquisition by Abbott (ABT).

2Preliminary results showed that more than 99% of the votes cast were in favor of the deal.

3The votes in favor represent approximately 67% of the total outstanding shares of Exact Sciences.

Stockholders of Exact Sciences Corporation (EXAS) have formally voted to approve the proposed acquisition by Abbott Laboratories (ABT). Preliminary results from the special meeting indicate that more than 99% of the votes cast were in favor of the merger. The affirmative votes represent approximately 67% of the total outstanding shares of Exact Sciences, signaling strong investor backing for the deal. This approval marks a critical regulatory and corporate milestone in the process of finalizing the acquisition of the cancer screening and diagnostic test provider. The transaction is expected to significantly bolster Abbott's position within the global healthcare and diagnostics market. By removing a major hurdle, the vote provides clarity for the combined entity's future expansion strategy and long-term growth prospects.